Aim Research in Merewether has been invited to participate in a new clinical study for people living with type 2 diabetes (T2D), cardiovascular disease and high blood pressure.
People who live with these conditions are more likely to develop a health condition where the heart does not pump blood around the body as well as it should. The medical term for this is heart failure. Heart failure may sound alarming, but it doesn’t mean that the heart is about to stop. It simply means that the heart doesn’t pump blood around the body as well as it should and it may need some support to help it work better. Our blood carries the nutrients and oxygen our bodies need to thrive. When the heart doesn’t pump blood as well as it should, it lowers the amount of oxygen that can work in the body.
Our mission is to prioritise finding treatments that may help prevent heart failure before it happens. That’s why we are carrying out a new clinical study in heart failure prevention called BaxDuo Prevent-HF.
BaxDuo Prevent-HF is looking at a combination of 2 different medications that may work together to lower your blood pressure and protect your kidneys more than dapagliflozin on its own.
To complete this study, we need volunteer participants. We are looking for volunteers who:
- Are ≥ 40 years old
- Have Type 2 Diabetes requiring treatment
- History of Hypertension (high blood pressure)
- Have had a heart attack, heart bypass, stents in heart, or have >50% blockage in 2 heart arteries
Those who choose to volunteer and meet the eligibility criteria will need to participate for the duration of the trial, visiting our clinic in Merewether regularly during this period for review and to collect their study medication. You will be reimbursed for your time.
If you meet the above criteria and are interested in knowing more, please complete the form below, and one of our Clinical Trial Coordinators will be in contact with you soon.
Once completed and submitted, the form will be automatically sent to CRIO, a secure clinical trial management database held by Aim Research. All patient information received will be kept in a confidential manner, and reviewed by our team of researchers to ascertain eligibility.
